International law firm CMS has advised Amber Therapeutics, a UK based medical technology company, on its USD 100m Series A fundraising round. The round was led by New Enterprise Associates, with F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises and 8VC also participating.
Amber Therapeutics was founded in 2021 with a mission to transform outcomes in areas of unmet clinical need through breakthrough neuromodulation therapies. Its first therapy, called Amber-UI, aims to restore normal bladder function in women suffering from mixed urinary incontinence. The funds raised will allow Amber Therapeutics to fund the development of Amber-UI through pilot and pivotal studies towards regulatory approval for Amber-UI in the US.
CMS Corporate Partner Simon Morgan comments: “We are pleased to have advised Amber Therapeutics on this successful Series A fundraising round, which has attracted leading healthcare and technology investors from the US and UK. The CMS team’s extensive experience working with medical device and life sciences businesses means that it was ideally placed to advise Amber Therapeutics on this fundraising.”
The CMS team was led by Simon Morgan, and included Sarah Hanson (Life Sciences) and Gemma Hall, Cameron Jones and Lisa Franco (Corporate).
